KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,304,588 | +614.9% | 448,701 | +801.0% | 0.00% | – |
| Q2 2023 | $2,000,884 | -66.8% | 49,798 | -64.7% | 0.00% | -100.0% |
| Q1 2023 | $6,019,420 | -12.3% | 140,970 | -1.4% | 0.00% | 0.0% |
| Q4 2022 | $6,864,987 | +196.7% | 142,961 | +132.4% | 0.00% | – |
| Q3 2022 | $2,314,000 | -30.1% | 61,521 | -48.6% | 0.00% | – |
| Q2 2022 | $3,310,000 | +17.4% | 119,798 | +131.1% | 0.00% | – |
| Q1 2022 | $2,819,000 | +576.0% | 51,828 | +625.8% | 0.00% | – |
| Q4 2021 | $417,000 | -86.9% | 7,141 | -91.1% | 0.00% | – |
| Q3 2021 | $3,173,000 | +225.1% | 80,212 | +249.1% | 0.00% | – |
| Q2 2021 | $976,000 | +5322.2% | 22,980 | +7907.0% | 0.00% | – |
| Q1 2021 | $18,000 | -99.7% | 287 | -99.6% | 0.00% | -100.0% |
| Q4 2020 | $5,336,000 | +22133.3% | 75,635 | +11963.0% | 0.00% | – |
| Q3 2020 | $24,000 | -70.4% | 627 | -70.9% | 0.00% | – |
| Q2 2020 | $81,000 | – | 2,153 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |